Cluster identification, selection, and description in cluster randomized crossover trials: the PREP-IT trials

Sheila Sprague, Taryn Scott, Shannon Dodds, David Pogorzelski, Paula McKay, Anthony D Harris, Amber Wood, Lehana Thabane, Mohit Bhandari, Samir Mehta, Greg Gaski, Christina Boulton, Francesc Marcano-Fernández, Ernesto Guerra-Farfán, Joan Hebden, Lyndsay M O'Hara, Gerard P Slobogean, PREP-IT Investigators, Sheila Sprague, Taryn Scott, Shannon Dodds, David Pogorzelski, Paula McKay, Anthony D Harris, Amber Wood, Lehana Thabane, Mohit Bhandari, Samir Mehta, Greg Gaski, Christina Boulton, Francesc Marcano-Fernández, Ernesto Guerra-Farfán, Joan Hebden, Lyndsay M O'Hara, Gerard P Slobogean, PREP-IT Investigators

Abstract

Background: In cluster randomized crossover (CRXO) trials, groups of participants (i.e., clusters) are randomly allocated to receive a sequence of interventions over time (i.e., cluster periods). CRXO trials are becoming more comment when they are feasible, as they require fewer clusters than parallel group cluster randomized trials. However, CRXO trials have not been frequently used in orthopedic fracture trials and represent a novel methodological application within the field. To disseminate the early knowledge gained from our experience initiating two cluster randomized crossover trials, we describe our process for the identification and selection of the orthopedic practices (i.e., clusters) participating in the PREP-IT program and present data to describe their key characteristics.

Methods: The PREP-IT program comprises two ongoing pragmatic cluster randomized crossover trials (Aqueous-PREP and PREPARE) which compare the effect of iodophor versus chlorhexidine solutions on surgical site infection and unplanned fracture-related reoperations in patients undergoing operative fracture management. We describe the process we used to identify and select orthopedic practices (clusters) for the PREP-IT trials, along with their characteristics.

Results: We identified 58 potential orthopedic practices for inclusion in the PREP-IT trials. After screening each practice for eligibility, we selected 30 practices for participation and randomized each to a sequence of interventions (15 for Aqueous-PREP and 20 for PREPARE). The majority of orthopedic practices included in the Aqueous-PREP and PREPARE trials were situated in level I trauma centers (100% and 87%, respectively). Orthopedic practices in the Aqueous-PREP trial operatively treated a median of 149 open fracture patients per year, included a median of 11 orthopedic surgeons, and had access to a median of 5 infection preventionists. Orthopedic practices in the PREPARE trial treated a median of 142 open fracture and 1090 closed fracture patients per year, included a median of 7.5 orthopedic surgeons, and had access to a median of 6 infection preventionists.

Conclusions: The PREP-IT trials provide an example of how to follow the reporting standards for cluster randomized crossover trials by providing a clear definition of the cluster unit, a thorough description of the cluster identification and selection process, and sufficient description of key cluster characteristics.

Trial registration: Both trials are registered at ClinicalTrials.gov (A-PREP: NCT03385304 December 28, 2017, and PREPARE: NCT03523962 May 14, 2018).

Keywords: Cluster; Cluster characteristics; Orthopedic; Pragmatic; Randomized crossover; Surgical site infection.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
The PREP-IT research program
Fig. 2
Fig. 2
PREPARE CONSORT flowchart for clusters
Fig. 3
Fig. 3
Aqueous-PREP CONSORT flowchart for clusters
Fig. 4
Fig. 4
Overview of the PREP-IT cluster identification, selection, and randomization processes

References

    1. Sackett D. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest. 1989;95(2 Suppl):2S–4S. doi: 10.1378/chest.95.2_Supplement.2S.
    1. Arnup SJ, Forbes AB, Kahan BC, Morgan KE, McDonald S, McKenzie JE. The use of the cluster randomized crossover design in clinical trials: protocol for a systematic review. Syst Rev. 2014. 10.1186/2046-4053-3-86.
    1. Arnup SJ, McKenzie JE, Hemming K, Pilcher D, Forbes AB. Understanding the cluster randomised crossover design: a graphical illustraton of the components of variation and a sample size tutorial. Trials. 2017. 10.1186/s13063-017-2113-2.
    1. Campbell MK, Piaggio G, Elbourne DR, Altman DG. CONSORT 2010 statement: extension to cluster randomised trials. BMJ. 2012;345(sep04 1):e5661. doi: 10.1136/bmj.e5661.
    1. Arnup SJ, Forbes AB, Kahan BC, Morgan KE, McKenzie JE. The quality of reporting in cluster randomised crossover trials: proposal for reporting items and an assessment of reporting quality. Trials. 2016. 10.1186/s13063-016-1685-6.
    1. Program of Randomized Trials to Evaluate Pre-operative Antiseptic Skin Solutions in Orthopaedic Trauma (PREP-IT) Investigators, Slobogean GP, Sprague S, Wells J, Bhandari M, Rojas A, Garibaldi A, Wood A, Howe A, Harris AD, Petrisor BA, Mullins DC, Pogorzelski D, Marvel D, Heels-Ansdell D, Mossuto F, Grissom F, Del Fabbro G, Guyatt GH, Della Rocca GJ, Nguyen U, et al. Effectiveness of iodophor vs chlorhexidine solutions for surgical site infections and unplanned reoperations for patients who underwent fracture repair: the PREP-IT master protocol. JAMA Network Open. 2020;3(4):e202215. 10.1001/jamanetworkopen.2020.2215.
    1. Centers for Disease Control and Prevention (CDC) Surgical site infection (SSI) event. 2017.
    1. Ford I, Norrie J. Pragmatic trials. N Engl J Med. 2016. 10.1056/NEJMra1510059.

Source: PubMed

3
Předplatit